subject closer inspection possibly premarket approval important scans analytically clinically accurate individuals not misled incorrect test results unsupported clinical interpretations alberto gutierrez head fda wrote letters companies pulling tests market immediately fda plans evaluate claims company making data law gutierrez explains tests depending vital potentially risky information tests claim provide services evaluated differently test going people risk assessment kid going bald grow think low risk says test offering predict person body going metabolize drug risk information misused concerned working industry voiced support government guidance welcome interest pearson says fda inquiries adds group shares agency concern new technologies reliably accurately fda